Drug–Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers

BACKGROUND AND AIMS: The three direct-acting antiviral regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir (3D regimen) is approved for treatment of hepatitis C virus (HCV) genotype 1 infection. Drug–drug interaction (DDI) studies of the 3D regimen and commonly used medications were conducted...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Pharmacokinet
Auteurs principaux: Polepally, Akshanth R., King, Jennifer R., Ding, Bifeng, Shuster, Diana L., Dumas, Emily O., Khatri, Amit, Chiu, Yi-Lin, Podsadecki, Thomas J., Menon, Rajeev M.
Format: Artigo
Langue:Inglês
Publié: Springer International Publishing 2016
Sujets:
Original Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4933729/
https://ncbi.nlm.nih.gov/pubmed/26895022
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40262-016-0373-8
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires